

Application No: 09/926,286
Filed January 15, 2002
Atty. Docket: 2965-0159

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for reducing invasiveness and/or migration of malignant cells in a patient in need of such reduction comprising ~~The use of~~ administering to the patient an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivatives derivative thereof for the preparation of antimetastatic medicaments in an invasiveness and/or migration of malignant cells reducing effective amount, and a pharmaceutically acceptable carrier therefor.
2. (Currently amended) ~~The use as claimed in method of~~ claim 1 wherein the said at least one physiologically equivalents derivatives equivalent derivative of alpha lipoic acid ~~are selected from salts, esters~~ is a salt, ester or inclusion complexes complex.
3. (Currently amended) ~~The use as claimed in method of~~ claim 2 wherein the lipoic acid derivative said salt is a pharmaceutically acceptable salt.
4. (Currently amended) ~~The use as claimed in method of~~ claim 1 ~~for the preparation of antimetastatic medicaments which can be~~ wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof is administered orally, intravenously or subcutaneously through the oral, intravenous or subcutaneous routes.

Application No: 09/926,286
Filed January 15, 2002
Atty. Docket: 2965-0159

5. (New) The method of claim 1 wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof is administered topically, rectally or by inhalation.

6. (New) The method of claim 1, wherein said active ingredient is administered in a daily dose of about 0.5 to about 5g.

7. (New) The method of claim 1, wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof reduces invasiveness of malignant cells.

8. (New) The method of claim 1, wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof reduces migration of malignant cells.

9. (New) A method for promoting adhesion of malignant cells in a patient in need of such promotion comprising

administering to the patient a composition comprising an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in an adhesion of malignant cells promoting effective amount, and a pharmaceutically acceptable carrier therefor.

10. (New) A method according to claim 10, wherein said adhesion is adhesion to a

Application No: 09/926,286
Filed January 15, 2002
Atty. Docket: 2965-0159

basal membrane.

11. (New) A method for reducing metastasis in a patient in need of such treatment comprising

administering to the patient a composition comprising an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in a metastasis reducing effective amount, and a pharmaceutically acceptable carrier therefor.

12. (New) The method of claim 11 wherein said at least one physiologically equivalent derivative of alpha lipoic acid is a salt, ester or inclusion complex.

13. (New) The method of claim 12 wherein said salt is a pharmaceutically acceptable salt.

14. (New) The method of claim 11 wherein said composition is administered orally, intravenously or subcutaneously.

15. (New) The method of claim 11 wherein said composition is administered topically, rectally or by inhalation.

Application No: 09/926,286
Filed January 15, 2002
Atty. Docket: 2965-0159

C1
16. (New) The method of claim 11, wherein said composition is administered in a daily dose of about 0.5 to about 5g.

17. (New) The method of claim 11, wherein metastasis is prevented.
